The incomplete nature of multiple sclerosis relapse resolution

Journal of the Neurological Sciences

Volumn 256, Issue SUPPL. 1, 2007, Pages

  Lublin, Fred D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical course; Disability; MRI; Multiple sclerosis; Natural history; PPMS; PRMS; Relapse; RRMS; SPMS; Worsening

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; PLACEBO;

ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RELAPSE; RELAPSING REMITTING MULTIPLE SCLEROSIS; REMISSION; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS; DISABILITY EVALUATION; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION; RECURRENCE; TIME FACTORS;

EID: 34147102393     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2007.01.062     Document Type: Article

References (15)

1. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
2. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study 1. Clinical course and disability. Brain 112 (1989) 133-146
3. Compston A., and Coles A. Multiple sclerosis. Lancet 359 (2002) 1221-1231
4. Weinshenker B.G., Bass B., Rice G.P., Noseworthy J., Carriere W., Baskerville J., et al. The natural history of multiple sclerosis: a geographically based study 2. Predictive value of the early clinical course. Brain 112 (1989) 1419-1428
5. Sormani M.P., Bruzzi P., Comi G., and Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology 58 (2002) 417-421
6. Held U., Heigenhauser L., Shang C., Kappos L., and Polman C.H. Predictors of relapse rate in MS clinical trials. Neurology 65 (2005) 1769-1773
7. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med 338 (1998) 278-285
8. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 45 (1995) 1268-1276
9. Johnson K.P., Brooks B.R., Ford C.C., Goodman A., Guarnaccia J., Lisak R.P., et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 6 (2000) 255-266
10. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39 (1996) 285-294
11. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon-beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
12. PRISMS Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon β-1a in relapsing MS. Neurology 56 (2001) 1628-1636
13. Lublin F.D., Baier M., and Cutter G.R. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61 (2003) 1528-1532
14. Confavreux C., Vukusic S., Moreau T., and Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 343 (2000) 1430-1438
15. Confavreux C., Vukusic S., and Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126 (2003) 770-782